Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Ighovwerha Ofotokun(Emory University), M. Adams, Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Angelina Villası́s-Keever(Bristol-Myers Squibb (United States)), Frain Jb, Heather J. Ribaudo(Cancer Research And Biostatistics), B. Taiwo, Jeffrey L. Lennox(Emory University), M. Palmer, J. Baer, Catherine Godfrey(United States Department of State), M. Dube(Goddard Space Flight Center), E. Seefried, M. Saemann, Manish Sagar(Evidence (Italy)), Raphael J. Landovitz(APLA Health), Susan E. Cohn(Brigham and Women's Hospital), Daniel R. Kuritzkes(Brigham and Women's Hospital), T. Spitz, Bryan Baugh(Brigham and Women's Hospital), C. Basler, Francesca Aweeka(University of California, San Francisco), Todd T. Brown(Johns Hopkins University), B. Santos, E. Lindsey, L. Meixner, A. Thomas, Judith S. Currier(University of California, Los Angeles), V. BAILEY, B. Putnam, Daar Es, S A Shaik, Michael F. Para(The Ohio State University), Kristine B. Patterson(University of North Carolina at Chapel Hill), Lumine H Na(Harvard University), F. Moran, T. James, P. Tebas, R. Basham, I. B. Dueno, R. Bedimo, B. Berzins, E. Chang, D. Currin, D. Cohn, M. Mba, J. L. S. Bagur, Grace A. McComsey(University Hospitals of Cleveland), M. Chicurel-Bayard, SL Koletar
Clinical Infectious Diseases
March 12, 2015
Cited by 82


Related Papers